Several members of the tumor necrosis receptor family superfamily [6] (TNFRSF) including TNFR2 [7], GITR [8], OX-40 [9], and 4-1BB [10, 11], chemokine receptors (CCR4 [12], CCR8 [13]) and co-inhibitory receptors (CTLA-4 [14–17], PD-1 [18, 19], LAG-3 [20], and Tim-3 [21]) appear to have enhanced expression on intra-tumoral Treg. While mAbs to some of these targets (CTLA-4, PD-1, CCR4 and CCR8) have anti-tumor effects by acting on Treg, the other targets are frequently expressed on activated Tconv populations and have not yet proven useful for the augmentation of tumor immunity. Here, TNFRSF18 is linked to neoplasm.